AbbVie has a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Pfizer is launching seven phase 3 studies for PF-4044 soon and plans to initiate an additional 10 (at least) by the end of ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...

And one of them is pharmaceutical giant Pfizer (NYSE: PFE). Now, with a major step along the path to entering this ...

Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages.

Dear reader, oncology medications occupy a prominent position in the global pharmaceutical industry, representing one of the ...

With all that in mind, if you have $2,000 available to invest that isn't needed for monthly bills, to pay down short-term ...

The treatment strategy may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, each aimed at slowing disease progression and, in many cases, temporarily reducing the ...

Market is projected to expand at a robust CAGR of around 9% over the next five years, driven by the increasing incidence of cancer and chronic diseases, accelerating R&D investments, continuous ...

Pfizer's concerted effort to move beyond its pandemic-era business and establish a new growth foundation in oncology faced an unexpected challenge this week. A revelation concerning regulatory ...